Syndax Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

Syndax Pharmaceuticals

28/02/2025 13:44

Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to show a rise in quarterly revenue when it reports  results on March 3 for the period ending December 31 2024

The New York City-based  company is expected to report revenue of $85.912 million, according to the mean estimate from 13 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $35.50‚Äč, above‚Äč its last closing price of $15.28. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.14
-1.11
-0.98
Beat
11.9
Jun. 30 2024
-0.91
-0.91
-0.80
Beat
12.5
Mar. 31 2024
-0.96
-0.98
-0.85
Beat
13.1‚Äč
Dec. 31 2023
-0.97
-0.99
-1.00
Missed
-0.6
‚Äč‚ÄčSep. 30 2023
-0.80
-0.80
-0.73
Beat
8.2
Jun. 30 2023
-0.73
-0.73
-0.64
Beat
12.6‚Äč
Mar. 31 2023
-0.60
-0.60
-0.59
Beat
1
Dec. 31 2022
-0.65
-0.65
-0.62
Beat
4.4

This summary was machine generated February 28 at 13:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)